HK1043113A1 - 端粒酶抑制劑及其使用方法 - Google Patents
端粒酶抑制劑及其使用方法Info
- Publication number
- HK1043113A1 HK1043113A1 HK02102943.2A HK02102943A HK1043113A1 HK 1043113 A1 HK1043113 A1 HK 1043113A1 HK 02102943 A HK02102943 A HK 02102943A HK 1043113 A1 HK1043113 A1 HK 1043113A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- telomerase inhibitors
- telomerase
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14217399P | 1999-07-01 | 1999-07-01 | |
JP18761699 | 1999-07-01 | ||
JP30757699A JP2001072592A (ja) | 1999-07-01 | 1999-10-28 | テロメラーゼ阻害剤 |
PCT/US2000/018211 WO2001002377A1 (fr) | 1999-07-01 | 2000-06-30 | Inhibiteurs de telomerase et leurs procedes d'utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1043113A1 true HK1043113A1 (zh) | 2002-09-06 |
Family
ID=27325921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK02102943.2A HK1043113A1 (zh) | 1999-07-01 | 2002-04-18 | 端粒酶抑制劑及其使用方法 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1109796A1 (fr) |
JP (1) | JP2003507473A (fr) |
KR (1) | KR20010099634A (fr) |
CN (1) | CN1321153A (fr) |
AU (1) | AU6340600A (fr) |
CA (1) | CA2341253A1 (fr) |
HK (1) | HK1043113A1 (fr) |
ID (1) | ID29875A (fr) |
WO (1) | WO2001002377A1 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1376150A (zh) * | 1999-07-26 | 2002-10-23 | 盐野义制药株式会社 | 具有血栓形成素受体拮抗作用的药物组合物 |
DE60115132T2 (de) * | 2000-04-21 | 2006-07-06 | Pfizer Products Inc., Groton | Thyroid-Rezeptorliganden |
US6620830B2 (en) | 2000-04-21 | 2003-09-16 | Pfizer, Inc. | Thyroid receptor ligands |
EP1276730A2 (fr) * | 2000-04-24 | 2003-01-22 | ARYx Therapeutics | Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose |
US6958355B2 (en) | 2000-04-24 | 2005-10-25 | Aryx Therapeutics, Inc. | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
US6768008B2 (en) * | 2000-04-24 | 2004-07-27 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
US6784199B2 (en) | 2000-09-21 | 2004-08-31 | Aryx Therapeutics | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals |
US6680387B2 (en) | 2000-04-24 | 2004-01-20 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
DE10133665A1 (de) * | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
WO2003018011A1 (fr) | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | 5-(substitue)-5-(substitue sulfonyl ou sulfanyl)thiazolidine-2,4-diones utiles pour l'inhibition de la farnesyl-proteine transferase |
US7045523B2 (en) | 2001-10-18 | 2006-05-16 | Novartis Ag | Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor |
GB0204252D0 (en) * | 2002-02-23 | 2002-04-10 | Oxford Glycosciences Uk Ltd | Novel compounds |
WO2004028535A1 (fr) * | 2002-09-26 | 2004-04-08 | Pintex Pharmaceuticals, Inc. | Composes de modulation de pin-1 et leurs procedes d'utilisation |
US7781464B2 (en) * | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
US6794401B2 (en) | 2003-01-17 | 2004-09-21 | Bexel Pharmaceuticals, Inc. | Amino acid phenoxy ethers |
US7521465B2 (en) | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
WO2004093803A2 (fr) * | 2003-04-16 | 2004-11-04 | Pintex Pharmaceuticals, Inc. | Composes photochimiotherapeutiques utilises dans le traitement d'etats associes a pin1 |
US7087576B2 (en) | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
FI20041129A0 (fi) * | 2004-08-30 | 2004-08-30 | Ctt Cancer Targeting Tech Oy | Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi |
CA2580811C (fr) | 2004-09-28 | 2014-04-08 | Otsuka Pharmaceutical Co., Ltd. | Derive de carbostyrile |
FR2887444A1 (fr) * | 2005-06-28 | 2006-12-29 | Oreal | Composes benzylidene-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute et/ou augmenter leur densite. |
KR100814109B1 (ko) | 2006-01-09 | 2008-03-14 | 한국생명공학연구원 | 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물 |
TWI315304B (en) * | 2006-08-31 | 2009-10-01 | Univ Taipei Medical | Indoline-sulfonamides compounds |
WO2008109731A2 (fr) * | 2007-03-07 | 2008-09-12 | Jassen Pharmaceutica N.V. | Phénoxythiazolidinediones n-alkylées en tant que modulateurs du récepteur-α œstrogénique |
EP2217235A4 (fr) * | 2007-11-15 | 2011-01-12 | Musc Found For Res Dev | Inhibiteurs de protéines kinases pim, compositions et procédés pour traiter le cancer |
TWI461423B (zh) * | 2008-07-02 | 2014-11-21 | Astrazeneca Ab | 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物 |
CN101973893B (zh) * | 2010-09-07 | 2013-07-17 | 黑龙江省科学院石油化学研究院 | 4-[2-(1-苯乙烯基)]-n,n-二(4-溴苯基)苯胺的合成方法 |
KR101817287B1 (ko) * | 2016-01-08 | 2018-01-10 | 조선대학교 산학협력단 | 티아졸리딘디온 유도체 및 그의 용도 |
CN116217511B (zh) * | 2023-03-22 | 2024-04-19 | 沈阳药科大学 | 一种双靶点化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5697277A (en) * | 1980-01-07 | 1981-08-05 | Takeda Chem Ind Ltd | Thiazolidine derivative |
JPS58118577A (ja) * | 1982-01-07 | 1983-07-14 | Takeda Chem Ind Ltd | チアゾリジン誘導体 |
CN1003445B (zh) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
US4738972A (en) * | 1985-05-21 | 1988-04-19 | Pfizer Inc. | Hypoglycemic thiazolidinediones |
US4812570A (en) * | 1986-07-24 | 1989-03-14 | Takeda Chemical Industries, Ltd. | Method for producing thiazolidinedione derivatives |
WO1989008650A1 (fr) * | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Agents hypoglycemiques de thiazolidinedione |
WO1989008651A1 (fr) * | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Derives de thiaxolidinedione hypoglycemiques |
IE940525L (en) * | 1988-05-25 | 1989-11-25 | Warner Lambert Co | Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents |
US5143929A (en) * | 1991-05-09 | 1992-09-01 | Warner-Lambert Company | 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents |
US6251928B1 (en) * | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
US5814647A (en) * | 1997-03-04 | 1998-09-29 | Board Of Regents, The University Of Texas System | Use of troglitazone and related compounds for the treatment of the climacteric symptoms |
-
2000
- 2000-06-30 JP JP2001518671A patent/JP2003507473A/ja not_active Withdrawn
- 2000-06-30 KR KR1020017002632A patent/KR20010099634A/ko not_active Application Discontinuation
- 2000-06-30 CA CA002341253A patent/CA2341253A1/fr not_active Abandoned
- 2000-06-30 WO PCT/US2000/018211 patent/WO2001002377A1/fr not_active Application Discontinuation
- 2000-06-30 CN CN00801875A patent/CN1321153A/zh active Pending
- 2000-06-30 ID IDW20010734A patent/ID29875A/id unknown
- 2000-06-30 AU AU63406/00A patent/AU6340600A/en not_active Abandoned
- 2000-06-30 EP EP00950282A patent/EP1109796A1/fr not_active Withdrawn
-
2002
- 2002-04-18 HK HK02102943.2A patent/HK1043113A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2341253A1 (fr) | 2001-01-11 |
WO2001002377A9 (fr) | 2001-10-11 |
EP1109796A1 (fr) | 2001-06-27 |
JP2003507473A (ja) | 2003-02-25 |
WO2001002377A1 (fr) | 2001-01-11 |
CN1321153A (zh) | 2001-11-07 |
AU6340600A (en) | 2001-01-22 |
KR20010099634A (ko) | 2001-11-09 |
ID29875A (id) | 2001-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1043113A1 (zh) | 端粒酶抑制劑及其使用方法 | |
GB2374100B (en) | Underreamer and method of use | |
HK1048247A1 (en) | Stable carotene-xanthophyll beadlet compositions and methods of use | |
AU7593001A (en) | Alpha-msh related compounds and methods of use | |
IL148657A0 (en) | Stent range transducers and methods of use | |
IL144214A0 (en) | Benzoheterocycles and their use as mek inhibitors | |
HK1068874A1 (en) | Heterocyclic compounds and methods of use | |
EP1227821A4 (fr) | Compositions therapeutiques et leurs procedes d'utilisation | |
EP1448218A4 (fr) | Inhibiteurs de la beta-secretase et leurs procede d'utilisation | |
AU2002225954A1 (en) | Dipeptidylpeptidases and methods of use | |
EP1183030A4 (fr) | Procede de fabrication et d'application de n-desmethylzopiclone | |
AU1334602A (en) | Osteopontin-coated surfaces and methods of use | |
AU2002213346A1 (en) | Osteopontin-coated surfaces and methods of use | |
GB2367103B (en) | Connector and method of use of the connector | |
PL361733A1 (en) | Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors | |
AU2001255696A1 (en) | Telomerase inhibitors and methods of their use | |
AU2002363938A8 (en) | Methods and use of motoneuronotropic factors | |
HUP0204376A3 (en) | Novel invertase inhibitors and methods of use | |
IL152792A0 (en) | Heterocycle derivatives and methods of use | |
EP1161451A4 (fr) | Endokine alpha humain et methodes d'utilisation | |
EP1263935A4 (fr) | Scytonemine et ses procedes d'utilisation | |
AU2002306845A1 (en) | Telomerase inhibitors and methods of their use | |
AU2001275381A1 (en) | Telomerase inhibitors and methods of their use | |
SG90719A1 (en) | Novel therapeutic and prophylactic agents and methods of using same | |
EP1392460A4 (fr) | Hydrofluorures d'aminosilanols et leur utilisation |